EphA8在非小细胞肺癌中的表达及其预后价值

Prognostic value of EphA8 expression in non-small cell lung cancer

目的:探讨EphA8(ephrin type-A receptor 8)在非小细胞肺癌(non-small cell lung cancer,NSCLC)中的表达及其与患者临床病理特征和预后的关系。方法:收集167例NSCLC术后石蜡包埋的组织标本,制作组织芯片,利用免疫组织化学技术测定EphA8蛋白在肿瘤组织中的表达情况,分析EphA8蛋白表达与患者临床病理特征及5年生存率的相关性。结果:NSCLC肿瘤组织中EphA8蛋白阳性表达率为54.5%,其表达水平与肿瘤大小、TNM分期、原发肿瘤分级及淋巴结转移有关,差异具有统计学意义(P<0.05)。单因素Cox回归分析显示,EphA8表达(P=0.030)及肿瘤大小(P=0.012)是影响NSCLC患者生存率的重要因素;多因素Cox回归分析显示,EphA8表达(P=0.046)及肿瘤大小(P=0.018)是NSCLC独立的预后因素,EphA8高表达、肿瘤体积大预示患者预后不良。Kaplan-Meier生存曲线分析显示,EphA8高表达患者5年总生存率低于EphA8低表达患者,肿瘤直径≥3 cm患者5年总生存率低于肿瘤直径<3 cm患者,差异均有统计学意义(P<0.05)。结论:EphA8可作为临床评估NSCLC的预后指标,高表达提示患者预后不良。

Objective:To investigate the expression of EphA8(ephrin type-A receptor 8) in non-small cell lung cancer(NSCLC), and to analyze the correlations of EphA8 expression with clinicopathological factors and prognosis in NSCLC.Methods:Lung adenocarcinoma tissues were obtained from 167 patients undergoing primary surgical resection for lung adenocarcinoma. The expression of EphA8 was detected by immunohistochemistry(IHC) with tissue microarrays(TMAs) in167 NSCLC samples. The correlation of clinicopathological parameters, the 5-year survival rate and EphA8 immunoreactivity of NSCLC patients were assessed. Results:EphA8 expression was significantly upregulated in lung cancer tissues of patients with lymph node metastasis(54.5%,91/167). EphA8 expression was significantly correlated with Tumor size, TNM stage, T and Lymphnode metastasis. Differences were considered statistically significant(P<0.05). Univariate analyses indicated that EphA8 expression(P=0.030) and tumor size(P=0.012) were associated with poor prognosis of NSCLC patients.Multivariate analyses further revealed that EphA8 expression(P=0.046) and tumor size(P=0.018) were independent prognostic factors. Kaplan-Meier survival curves and bioinformatic analysis showed that patients whose tumor tissues exhibited high expression of EphA8 had significantly shorter overall survival(OS) than patients with low expression. Conclusion:High expression of EphA8 was significantly associated with poor prognosis after surgical treatment in NSCLC. EphA8 could be used as a new prognostic biomarker of NSCLC.